E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis

Oncotarget

Volumn 5, Issue 23, 2014, Pages 12097-12110

  Yasmin Karim, Sayeda ^a   King, Michael R ^b   Messing, Edward M ^a   Lee, Yi Fen ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b School of Operations Research and Industrial Engineering   (United States)

Author keywords

Cancer cell rolling and adhesion; Circulatory tumor cell; E selectin; E selectin ligand 1; Prostate cancer

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1 LIGAND 1; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; CYSTEINE-RICH FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; SIALOGLYCOPROTEIN; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL FUNCTION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC CODE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; CELL MOTION; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR EMBOLISM; TUMOR INVASION; XENOGRAFT;

ANIMALS; CELL ADHESION; CELL MOVEMENT; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIALOGLYCOPROTEINS; TRANSCRIPTOME;

EID: 84920054096     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2503     Document Type: Article

References (48)

1. Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer metastasis reviews. 1998; 17:331-336.
2. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nature reviews Cancer. 2007; 7:834-846.
3. Jacobs PP, Sackstein R. CD44 and HCELL: preventing hematogenous metastasis at step 1. FEBS letters. 2011; 585:3148-3158.
4. Bonnomet A, Brysse A, Tachsidis A, Waltham M, Thompson EW, Polette M, Gilles C. Epithelial-tomesenchymal transitions and circulating tumor cells. Journal of mammary gland biology and neoplasia. 2010; 15:261-273.
5. He H, Yang X, Davidson AJ, Wu D, Marshall FF, Chung LW, Zhau HE, Wang R. Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis. The Prostate. 2010; 70:518-528.
6. Gajula RP, Chettiar ST, Williams RD, Thiygarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, Burns TF, et al. The Twist Box Domain is Required for Twist1-induced Prostate Cancer Metastasis. Mol Cancer Res. 2013.
7. Carvalho FL, Simons BW, Antonarakis ES, Rasheed Z, Douglas N, Villegas D, Matsui W, Berman DM. Tumorigenic potential of circulating prostate tumor cells. Oncotarget. 2013; 4:413-421.
8. Dimitroff CJ, Lechpammer M, Long-Woodward D, Kutok JL. Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin. Cancer research. 2004; 64:5261-5269.
9. Barthel SR, Gavino JD, Wiese GK, Jaynes JM, Siddiqui J, Dimitroff CJ. Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology. 2008; 18:806-817.
10. Barthel SR, Hays DL, Yazawa EM, Opperman M, Walley KC, Nimrichter L, Burdick MM, Gillard BM, Moser MT, Pantel K, Foster BA, Pienta KJ, Dimitroff CJ. Definition of molecular determinants of prostate cancer cell bone extravasation. Cancer research. 2013; 73:942-952.
11. Sreeramkumar V, Leiva M, Stadtmann A, Pitaval C, Ortega-Rodriguez I, Wild MK, Lee B, Zarbock A, Hidalgo A. Coordinated and unique functions of the E-selectin ligand ESL-1 during inflammatory and hematopoietic recruitment in mice. Blood. 2013.
12. Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer research. 2005; 65:5750-5760.
13. Gout S, Morin C, Houle F, Huot J. Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer research. 2006; 66:9117-9124.
14. Tozeren A, Kleinman HK, Grant DS, Morales D, Mercurio AM, Byers SW. E-selectin-mediated dynamic interactions of breast-and colon-cancer cells with endothelial-cell monolayers. International journal of cancer Journal international du cancer. 1995; 60:426-431.
15. Fukuda MN, Ohyama C, Lowitz K, Matsuo O, Pasqualini R, Ruoslahti E, Fukuda M. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer research. 2000; 60:450-456.
16. Dallas MR, Chen SH, Streppel MM, Sharma S, Maitra A, Konstantopoulos K. Sialofucosylated podocalyxin is a functional E-and L-selectin ligand expressed by metastatic pancreatic cancer cells. American journal of physiology Cell physiology. 2012; 303:C616-624.
17. Li J, Guillebon AD, Hsu JW, Barthel SR, Dimitroff CJ, Lee YF, King MR. Human fucosyltransferase 6 enables prostate cancer metastasis to bone. Br J Cancer. 2013.
18. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert opinion on therapeutic targets. 2007; 11:1473-1491.
19. Laubli H, Borsig L. Selectins promote tumor metastasis. Seminars in cancer biology. 2010; 20:169-177.
20. Borsig L, Vlodavsky I, Ishai-Michaeli R, Torri G, Vismara E. Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia. 2011; 13:445-452.
21. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature reviews Immunology. 2007; 7:678-689.
22. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cellderived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer research. 2002; 62:1832-1837.
23. Hsu JW, Yasmin-Karim S, King MR, Wojciechowski JC, Mickelsen D, Blair ML, Ting HJ, Ma WL, Lee YF. Suppression of prostate cancer cell rolling and adhesion to endothelium by 1alpha, 25-dihydroxyvitamin D3. The American journal of pathology. 2011; 178:872-880.
24. Lapek JD, Jr., McGrath JL, Ricke WA, Friedman AE. LC/ LC-MS/MS of an innovative prostate human epithelial cancer (PHEC) in vitro model system. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2012; 893-894:34-42.
25. Bao BY, Ting HJ, Hsu JW, Yasmin-Karim S, Messing E, Lee YF. Down-regulation of NF-kappaB signals is involved in loss of 1alpha, 25-dihydroxyvitamin D3 responsiveness. J Steroid Biochem Mol Biol. 2010; 120:11-21.
26. Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. Mol Cancer Res. 2007; 5:967-980.
27. Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 2013; 4:106-117.
28. Amini S, Fathi F, Mobalegi J, Sofimajidpour H, Ghadimi T. The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines. Anatomy & cell biology. 2014; 47:1-11.
29. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95:1735-1740.
30. Guo G, Yao W, Zhang Q, Bo Y. Oleanolic acid suppresses migration and invasion of malignant glioma cells by inactivating MAPK/ERK signaling pathway. PloS one. 2013; 8:e72079.
31. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nature reviews Molecular cell biology. 2010; 11: 633-643.
32. Sackstein R. The bone marrow is akin to skin: HCELL and the biology of hematopoietic stem cell homing. The journal of investigative dermatology Symposium proceedings / the Society for Investigative Dermatology, Inc [and] European Society for Dermatological Research. 2004; 9:215-223.
33. Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, Tutt A, Taylor-Papadimitriou J, Pinder SE, Burchell JM. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer research. 2011; 71:7683-7693.
34. Gout S, Tremblay PL, Huot J. Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clinical & experimental metastasis. 2008; 25:335-344.
35. Hidalgo A, Peired AJ, Wild MK, Vestweber D, Frenette PS. Complete identification of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. Immunity. 2007; 26:477-489.
36. Steegmaier M, Levinovitz A, Isenmann S, Borges E, Lenter M, Kocher HP, Kleuser B, Vestweber D. The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature. 1995; 373:615-620.
37. Mourelatos Z, Gonatas JO, Nycum LM, Gonatas NK, Biegel JA. Assignment of the GLG1 gene for MGF-160, a fibroblast growth factor and E-selectin binding membrane sialoglycoprotein of the Golgi apparatus, to chromosome 16q22-q23 by fluorescence in situ hybridization. Genomics. 1995; 28:354-355.
38. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nature reviews Cancer. 2010; 10:116-129.
39. Zayzafoon M, Abdulkadir SA, McDonald JM. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. The Journal of biological chemistry. 2004; 279:3662-3670.
40. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene. 2003; 22:1381-1389.
41. Hsu WY, Chao YW, Tsai YL, Lien CC, Chang CF, Deng MC, Ho LT, Kwok CF, Juan CC. Resistin induces monocyte-endothelial cell adhesion by increasing ICAM-1 and VCAM-1 expression in endothelial cells via p38MAPK-dependent pathway. Journal of cellular physiology. 2011; 226:2181-2188.
42. King MR, Hammer DA. Multiparticle adhesive dynamics: hydrodynamic recruitment of rolling leukocytes. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98:14919-14924.
43. Rana K, Liesveld JL, King MR. Delivery of apoptotic signal to rolling cancer cells: a novel biomimetic technique using immobilized TRAIL and E-selectin. Biotechnology and bioengineering. 2009; 102:1692-1702.
44. Giavazzi R, Foppolo M, Dossi R, Remuzzi A. Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions. The Journal of clinical investigation. 1993; 92:3038-3044.
45. Fan X, Liu S, Su F, Pan Q, Lin T. Effective enrichment of prostate cancer stem cells from spheres in a suspension culture system. Urologic oncology. 2012; 30:314-318.
46. Ting HJ, Messing J, Yasmin-Karim S, Lee YF. Identification of microRNA-98 as a therapeutic target inhibiting prostate cancer growth and a biomarker induced by vitamin D. The Journal of biological chemistry. 2013; 288:1-9.
47. Demaret J, Walencik A, Jacob MC, Timsit JF, Venet F, Lepape A, Monneret G. Inter-laboratory assessment of flow cytometric monocyte HLA-DR expression in clinical samples. Cytometry Part B, Clinical cytometry. 2013; 84:59-62.
48. Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, Hsu CL, Chang C. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. International journal of cancer Journal international du cancer. 2008; 123:195-201.